Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

SC vedolizumab improves outcomes in patients with Crohn’s disease

Audrey Abella
12 Jun 2020

Maintenance therapy with a new subcutaneous (SC) formulation of the monoclonal antibody vedolizumab led to improvements in patient-reported outcomes (PROs) in patients with moderate-to-severe active Crohn’s disease (CD) compared with placebo, interim results of the phase III VISIBLE 2 study has shown.

“CD … can lead to structural bowel damage, thereby negatively affecting quality of life (QoL) and productivity … [Our findings show that] a numerically higher proportion of patients achieved clinical remission based on PROs [and] improved QoL and work productivity with vedolizumab SC … maintenance therapy,” said the researchers.

At week 52, clinical remission was achieved by more participants treated with vedolizumab vs placebo, as reflected by the Crohn’s Disease Activity Index (CDAI) PRO2* (40 percent vs 29 percent; p=0.026) and PRO3** scores (40 percent vs 31 percent; p=0.053), as well as the mean daily stool frequency subscore ≤1.5 with abdominal pain subscore ≤1 (29 percent vs 24 percent; p=0.263). [DDW 2020, abstract Sa1816]

Clinically meaningful improvements in Inflammatory Bowel Disease Questionnaire (IBDQ) scores were also observed in both arms at week 52, with a trend favouring vedolizumab over placebo (mean, +63.3 vs +55.1).

Euro QoL-5D (EQ-5D) index and EQ-5D visual analogue scale (EQ-5D-VAS) score were similarly improved in both vedolizumab and placebo arms (mean, +0.21 vs +0.16 [EQ-5D] and +27.7 vs +26.2 [EQ-5D-VAS]).

Reductions in mean WPAI-CD*** overall work productivity loss scores from baseline to week 52 were also seen in both arms, but more so in the vedolizumab vs the placebo arm (mean, –32.5 percent vs –28.1 percent).

 

Maintenance alternative

Following vedolizumab 300 mg IV induction (weeks 0 and 2), 412 participants (median age 34.8 years, 53 percent male) who had a clinical response at week 6 entered the maintenance phase and were randomized 2:1 to receive vedolizumab SC 108 mg Q2W or placebo for 52 weeks.

The current findings correlate with the primary results of this trial, showing that nearly half of vedolizumab recipients (48 percent) achieved clinical remission as per CDAI score ≤150. [J Crohns Colitis 2020;14:S020-S021] Taken together, the results underpin the clinical benefit of vedolizumab SC in this setting, they added.

The initially approved route of administration for vedolizumab was via IV, noted the researchers. Given the similar improvements in IBDQ and EQ-5D parameters between the current study and another trial evaluating vedolizumab IV, [N Engl J Med 2013;369:711-721] the new SC formulation may offer CD patients an alternative route of administration for maintenance treatment, they said.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.